Amanda K Krutke, ACNS-BC Clinical Nurse Specialist - Adult Health Medicare: Accepting Medicare Assignments Practice Location: 107 Omni Dr, Suite A, Seneca, SC 29672 Phone: 864-885-7886 |
News Archive
Nymox Pharmaceutical Corporation is pleased to report positive new results from the 48-60 month follow-up study of patients treated with NX-1207 in Study NX02-0014. The initial study, completed in the U.S. in 2006, reached statistical significance in Intent-to-Treat Primary Efficacy outcomes at 90 days post-treatment with NX-1207 2.5 mg.
Despite national guidelines recommending that inhaled corticosteroid (ICS) be used alone as the preferred treatment for patients with mild persistent asthma, a new study finds that nearly two-thirds of these patients are taking more costly drugs that combine an ICS and a long-acting beta agonist (LABA) with no apparent additional clinical benefit noted based on pharmacy and medical claims.
Bristol-Myers Squibb Company and AstraZeneca today announced results up to 76-weeks from a Phase 3 study of ONGLYZA(TM) (saxagliptin) as initial combination therapy with metformin, which produced long-term glycemic improvement (as measured by glycosylated hemoglobin level (HbA1c)) in treatment-naive adults with type 2 diabetes mellitus inadequately controlled on diet and exercise compared to treatment with an investigational 10 mg dose of saxagliptin or metformin alone.
Given Imaging Ltd. today announced that new data presented at the American College of Gastroenterology (ACG) 2009 Conference show that by visualizing the small bowel with the PillCamĀ® SB video capsule, physicians can detect the cause of occult gastrointestinal bleeding (OGIB) and adapt how they manage and treat these patients.
On March 4, the U.S. Supreme Court will hear oral arguments in King v. Burwell, a landmark case that takes aim at President Obama's Affordable Care Act (ACA).
› Verified 8 days ago